TScan Therapeutics Announces FDA Clearance Of Investigational New Drug Application For TSC-200-A0201 Targeting HPV16 To Treat Solid Tumors
Portfolio Pulse from Benzinga Newsdesk
TScan Therapeutics has received FDA clearance for its Investigational New Drug (IND) application for TSC-200-A0201, targeting HPV16 to treat solid tumors. This marks a significant milestone for the company's TCR-T cell therapy program.
June 06, 2023 | 11:05 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TScan Therapeutics' FDA clearance for its IND application of TSC-200-A0201 targeting HPV16 may positively impact the company's stock price.
The FDA clearance of TScan's IND application for TSC-200-A0201 is a significant milestone for the company's TCR-T cell therapy program. This regulatory approval may attract more investors and increase the demand for TCRX stock, leading to a potential short-term increase in its stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100